Cytokine News and Research

RSS

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

A pediatric immunologist at The Children's Hospital of Philadelphia collaborated with European gene therapy researchers who achieved marked clinical improvements in two young children with Wiskott-Aldrich syndrome, a very rare but often severe immunodeficiency disorder.

16 Nov 2010

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the November 21 issue of BioWorld Today in the NewCo section.

11 Nov 2010

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

Research on immune system may help in healing chronic inflammatory diseases

Biochemists at Kiel University, along with international scientists, have identified an important messenger in the immune system. The messenger interleukin-27 plays an important role when the human body blocks inflammations.

9 Nov 2010

Excess levels of TNF immune signaling protein key factor in AD

Three new studies provide converging evidence pointing to a new therapeutic target in Alzheimer's Disease(AD). These studies, from independent academic centers in the U.S., England, and China, point to excess levels of a protein called TNF as a key factor in AD. TNF is an immune signaling protein that regulates both inflammation and neuronal communication in the brain.

8 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

Arthritis drugs also prevent post-operative cognitive decline: Study

Anti-inflammatory drugs currently used to treat diseases such as rheumatoid arthritis may also help prevent cognitive problems after surgery, according to a new study by researchers at Imperial College London and University of California, San Francisco (UCSF).

2 Nov 2010

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Idera Pharmaceuticals, Inc. today announced results from its single-dose, dose-escalation Phase 1 clinical trial evaluating the safety and mechanism of action of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for the treatment of autoimmune and inflammatory diseases.

22 Oct 2010

Protein IL-37 could help treat inflammatory diseases in adults and children

A husband and wife research team from Melbourne, Australia, have identified a protein that may be a key therapy for many inflammatory diseases, including those affecting premature babies.

21 Oct 2010

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

A new study by a University of Arkansas biomedical engineer and his colleagues at the National Cancer Institute demonstrates further promise for chitosan/interleukin-12 as an effective anti-tumor immunotherapy.

13 Oct 2010

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

Scientists have found that a synthetic molecule they designed can block activation of a gene in liver cancer cells, halting a process that allows some of those cancer cells to survive chemotherapy.

13 Oct 2010

Researchers develop new approach to treat inflammatory bowel disease

Researchers at the Georgia Institute of Technology and Emory University have developed a novel approach for delivering small bits of genetic material into the body to improve the treatment of inflammatory bowel diseases. Delivering short strands of RNA into cells has become a popular research area because of its potential therapeutic applications, but how to deliver them into targeted cells in a living organism has been an obstacle.

11 Oct 2010

Childhood abuse may lead to physiological consequences later in life

Seemingly healthy adults, if they were abused or neglected during childhood, may suffer physiological consequences decades later. In research published online last week by the journal Neuropsychopharmacology, a team led by psychiatrists at Brown University and Butler Hospital found that healthy adults who reported being mistreated as kids appear to have an elevated inflammatory response to stress compared to adults who had happier childhoods.

8 Oct 2010

Unique genetic markers point to patient response to SCV-07 treatment

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the Company’s phase 2a proof of concept study of SCV-07 for the prevention of severe oral mucositis (OM; WHO grades 3-4) in patients with advanced head and neck cancer.

29 Sep 2010

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes.

29 Sep 2010

Researchers to develop vaccine for plague

Given the many pressing concerns of the day, fear of plague probably isn't what causes most Americans to lose sleep. But for those whose responsibility it is to combat bioterrorism, plague is among the highest priorities. Those charged with that mission include scientists like medical researcher Steve Smiley, whose lab at the Trudeau Institute is working to develop a vaccine that will protect the public against weaponized forms of plague.

21 Sep 2010

Scientists identify new pathway to control immune balance

St. Jude Children's Research Hospital scientists have identified a new pathway that helps control the immune balance through reciprocal regulation of specialized T lymphocytes, which play very different inflammatory roles.

21 Sep 2010

Arrayit installs microarray platform at NIH

Arrayit Corporation has completed installation and technical training of its proprietary microarray platform at the National Institute of Mental Health, National Institutes of Health, in Rockville, Maryland. In 2010, the NIH will invest more than $31.2 billion in medical research for the American people through 50,000 competitive grants to 325,000 researchers at 3,000 universities, hospitals, companies, medical schools and scientific institutions in the United States and around the world.

21 Sep 2010

Researchers identify protein essential for dendritic cell development

A protein called PU.1 is essential for the development of dendritic cells, the sentinels of the immune system, Walter and Eliza Hall Institute researchers in Melbourne, Australia, have shown.

20 Sep 2010